The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo’s targeted expectation of at least 25% weight loss. The press release ...
The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo's targeted expectation of at least 25% weight loss. The press release ...
The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo's targeted expectation of at least 25% weight loss. The press release ...
Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.
DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants provided overwhelmingly positive statements to investors concerning the details of, and expectations for, Novo ...
It has other candidates in its late-stage obesity pipeline, headed by CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide with semaglutide. Phase 3 results reported ...
Of course, like all wardrobe basics, there are several tiers of quality and prices for sweatshirts. You have your more affordable crewnecks, staples like Champion, H&M, and Russell, which fans ...
REUTERS/Tom Little/File Photo Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries ...
The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...
A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed to establish a conclusive benefit.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback